Compare Schlumberger NV (SLB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schlumberger NV vs Summit Therapeutics Inc — how do they compare? Schlumberger NV trades at $57.07 (market cap $84.74B), while Summit Therapeutics Inc trades at $17.55 (market cap $13.79B). The key difference: Schlumberger NV is far larger — about 6.1× Summit Therapeutics Inc's market cap, and Schlumberger NV pays a 2.07% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SLB | SMMT | |
|---|---|---|
Market Cap | $84.74B | $13.79B |
Sector | Energy | Health |
52-Week High | $60.10 | $26.38 |
52-Week Low | $31.72 | $12.43 |
Enterprise Value | $93.47B | $13.11B |
Dividend Yield | 2.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLB trades at $57.10, down 0.71% on the day, but remains near recent highs with a bullish technical trend. The company reported three consecutive quarterly earnings beats, with Q3 2026 expected at $0.62 EPS. Recent news highlights the $3.4 billion acquisition of Kelvion, expanding SLB's data center cooling business. Revenue for 2025 was $35.71 billion with a net income margin of 8.53%, though margins have softened from prior years. Analyst consensus is strongly bullish with an average price target of $63.00.
The outlook for SLB is positive, driven by strategic diversification into data centers and solid operational cash flow near $6.5 billion annually. Key risks include exposure to oil price volatility and integration challenges from the Kelvion deal. With 85% of analysts rating it a buy, the stock offers upside potential but requires monitoring of execution on new growth initiatives.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
